CHCWM – Cancer & Hematology Centers of West Michigan

XL092 (Exelixis)

XL092 (Exelixis)

 Description:   A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Mechanism of Action: Tyrosine Kinase Inhibitor targeting VEGFR2, MET, AXL, TAM (AXL and MER). 

Target Patient Population: Study currently has slots for monotherapy in clear cell RCC and combination therapy (with Avelumab or Atezolizumab) in advanced solid tumors.

Study Design:  Study drug is given orally daily.